EQS-News: Cantourage achieves another record revenue: EUR 11.1 million in April 2025

Not for direct or indirect publication or distribution within or in the United States of America, Australia, Canada or Japan or any other jurisdiction where such publication or distribution would be unlawful. Please note the important information at the end of this announcement.

PRESS RELEASE

Cantourage achieves another record revenue: EUR 11.1 million in April 2025

Berlin, 15 May 2025 – Cantourage Group SE (hereinafter ‘Cantourage’, ISIN: DE000A3DSV01, www.cantourage.com), Europe's leading publicly traded medical cannabis company, continues its dynamic growth trajectory. In April 2025, the company achieved the highest monthly revenue in its history at EUR 11.1 million, surpassing its previous record from March (EUR 10.7 million) in the very next month.

High-level growth stabilises – demand remains strong
The renewed revenue record confirms the unbroken demand for Cantourage products – both in Germany and in dynamically growing international markets such as the United Kingdom and Poland. Cantourage is excellently positioned to meet the continuing strong demand with optimised product availability, a stable supply chain and targeted expansion of processing capacities in Germany and Portugal.

About Cantourage
Cantourage is a leading European company in the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries.

Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since 11 November 2022 and is traded under the ticker symbol ‘HIGH’.

Press contacts
Pia Senkel | pia.senkel@tonka-pr.com | +49 (0) 173 3702649
Klaas Geller | klaas.geller@tonka-communications.de | +49 (0) 176 74717519

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).